Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neuren PharmaceuticalsFRA:NK9 52 EV-to-FCF is 15.36 as of Jul. 14, 2026, which is 12% below its 10-year median of 17.36. GuruFocus rates FRA:NK9 with a GF Score™ of 52/100 and a GF Value™ of €4.27 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 335 Biotechnology companies, Neuren Pharmaceuticals ranks better than 51.94% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Neuren Pharmaceuticals's Enterprise Value is €1,086.88 Mil.
Neuren Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €70.77 Mil. Therefore, Neuren Pharmaceuticals's EV-to-FCF for today is 15.36.
The historical rank and industry rank for Neuren Pharmaceuticals's EV-to-FCF or its related term are showing as below:
FRA:NK9'
s EV-to-FCF Range Over the Past 10 Years
Min: -232.59 Med: 17.36 Max: 867.37
Current: 14.34
During the past 13 years, the highest EV-to-FCF of Neuren Pharmaceuticals was 867.37. The lowest was -232.59. And the median was 17.36.
FRA:NK9's EV-to-FCF is ranked better than 51.94% of 335
companies
in the Biotechnology industry
Industry Median: 15.34
vs FRA:NK9: 14.34
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Neuren Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Neuren Pharmaceuticals's share price for today is €9.85.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Neuren Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.132.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Neuren Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuren Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuren Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Neuren Pharmaceuticals's EV-to-FCF falls into.
Neuren Pharmaceuticals's current Enterprise Value is €1,086.88 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Neuren Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €70.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuren Pharmaceuticals (FRA:NK9) has a EV-to-FCF of 15.36 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Neuren Pharmaceuticals and its competitors. This is 12% below median its historical median of 17.36. According to the industry distribution chart, Neuren Pharmaceuticals ranks #161 out of 335 companies in the Biotechnology industry, placing it in the top 48.1%.
Is Neuren Pharmaceuticals' EV-to-FCF too high?
Neuren Pharmaceuticals' current EV-to-FCF of 15.36 is 12% below median its 10-year median of 17.36. The Biotechnology industry median EV-to-FCF is 15.34. Neuren Pharmaceuticals' value of 15.36 is 0.1% above this industry median. Based on the distribution chart, Neuren Pharmaceuticals ranks #161 out of 335 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Neuren Pharmaceuticals has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuren Pharmaceuticals' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neuren Pharmaceuticals ranks #161 out of 335 companies for EV-to-FCF. This puts Neuren Pharmaceuticals in the upper half of its industry. The industry median EV-to-FCF is 15.34. Neuren Pharmaceuticals' value of 15.36 is 0.1% above this benchmark. While the company's 10-year median is 17.36 vs. the industry median of 15.34, Neuren Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.34, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuren Pharmaceuticals's current EV-to-FCF of 15.36 is 0.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Neuren Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuren Pharmaceuticals's current EV-to-FCF is 15.36, which is 12% below median its own 10-year median of 17.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuren Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Neuren Pharmaceuticals (FRA:NK9) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.27, compared to a current price of €9.85 — trading 130.7% above its estimated fair value. The current EV-to-FCF is 15.36, which is 12% below median its 10-year median of 17.36 and 0.1% above the Biotechnology industry median of 15.34. Neuren Pharmaceuticals' overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Neuren Pharmaceuticals (FRA:NK9), the current EV-to-FCF is 15.36 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuren Pharmaceuticals (FRA:NK9) Overvalued in 2026?
Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued.
The current stock price of €9.85 is trading 130.7% above its estimated GF Value™ of €4.27.
GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:NK9:
EV-to-FCF: 15.36 (12% below median its 10-year median of 17.36)
GF Value™: €4.27 vs. price of €9.85 (130.7% above fair value)
Industry Position: 0.1% above the Biotechnology median (#161 of 335)
No single metric tells the full story. See the FRA:NK9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
52GF Score
Get the complete analysis for FRA:NK9
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NK9 has been successfully added to your 
